Abstract
It has been established that atherosclerotic coronary artery disease is more frequent and more severe in diabetic compared to non-diabetic subjects, but the reason for the excess risk of developing coronary macroangiopathy in diabetes remains incompletely characterized. Various biochemical mechanisms speculated to being at the “heart” of diabetic cardiac and coronary macroangiopathy are reviewed in the present article. In doing so, this article presents evidence that the labyrinthine interactions of hyperglycemia, insulin resistance, and dyslipidemia in diabetes result in a pro-atherogenic phenotype. Furthermore, the diabetic milieu yields a complex (dys)metabolic environment characterized by chronic inflammation, procoagulability, impaired fibrinolysis, neovascularization abnormalities, and microvascular defects that cumulatively alter blood rheology, artery structure, and homeostasis of the endothelium. The contributory influences of these factors in the pathophysiology of coronary artery disease in diabetes are also discussed.
Similar content being viewed by others
References
Bandyopadhyay P (2006) Cardiovascular disease and diabetes mellitus. Drug News Perspect 19(6):369–375
Marchetti P, Copelli A, Gianarelli R (2007) Pathophysiological links between diabetes and heart disease. Medicographia 29(3):213–219
Kumar PJ, Clark M (2006) Diabetes mellitus and other disorders of metabolism. In: Kumar PJ, Clark M (eds) Textbook of medicine. Sanders, London, pp 1069–1122
Zimmet PZ, Alberti KG (2006) Globalisation and the non-communicable disease epidemic. Obesity (Silver Spring) 14(1):1–3. doi:10.1038/oby.2006.1
Kannel WB, McGee DL (1979) Diabetes and cardiovascular disease. The Framingham study. JAMA 241:2035–2038. doi:10.1001/jama.241.19.2035
Grundy SM, Brewer B, Cleeman JI et al. (2004) Definition of the metabolic syndrome. Report of the national heart, lung, blood Institute/American heart Association conference on scientific issues related to definition. Circulation 109:433–438. doi:10.1161/01.CIR.0000111245.75752.C6
Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome—a new worldwide definition. Lancet 366:1059–1062. doi:10.1016/S0140-6736(05)67402-8
Nigro J, Osman N, Dart MA et al (2006) Insulin resistance and atherosclerosis. Endocr Rev 27(3):242–259. doi:10.1210/er.2005-0007
Zimmet P, Defronzo R, Keen H (1997) International textbook of diabetes mellitus. Wiley, Chichester, pp 9–23
Horst D, Rau H, Walfish PJ et al (1997) CTLA4 alanine-17 confers genetic susceptibility to Graves’ disease and to type 1 diabetes mellitus. J Clin Endocr Metab 82(1):143–146. doi:10.1210/jc.82.1.143
Marso SP, Stern DM (2003) Diabetes and cardiovascular disease: integrating science and clinical medicine. Lippincott Williams and Wilkins, Philadelphia, pp 56–74
Diabetes UK (2007) Diabetes heartache: the hard reality of cardiovascular care for people with diabetes. Available via http://www.diabetes.org.uk/Documents/News/Heartache_report07.pdf. Accessed 16 May 2008
Diabetes UK (2004) Diabetes in the UK. Diabetes UK 2004, London. Available via http://www.diabetes.org.uk/Documents/pdf. Accessed 10 February 2008
British Medical Association (2004) Diabetes Mellitus: An update for healthcare professionals. BMA 2004, London. Available via http://www.bma.org.uk/ap.nsf/Content/Diabetes. Accessed 5 Apr 2008
Cameron J, Cruikshank JK (2007) Glucose, insulin, diabetes and mechanisms of arterial dysfunction. Clin Exp Pharmacol Physiol 34:677–682. doi:10.1111/j.1440-1681.2007.04659.x
Spinetti G, Kraenkel N, Emanueli C et al (2008) Diabetes and vessel wall remodelling: from mechanistic insights to regenerative therapies. Cardiovasc Res 78(2):265–273. doi:10.1093/cvr/cvn039
Peter R, Evans MC (2008) Management of diabetes in cardiovascular patients. Heart 94:369–375. Available via http://heart.bmj.com/cgi/content/extract/94/3/369?maxtosresourcetyCIT. Accessed 31 May 2008
Goodfellow J (1997) Microvascular heart disease in diabetes mellitus. Diabetologia 40:S130–S133. doi:10.1007/s001250051428
Grossman E, Messerli FH (1996) Diabetic and hypertensive heart disease. Ann Intern Med 125(4):304–310
Bracken NK, Qureshi MA, Singh J et al (2003) Mechanism underlying contractile dysfunction in streptozotocin induced type 1 and type diabetic cardiomyopathy. In: Dhalla NS et al (eds) Atherosclerosis, hypertension and diabetes. Kluwer Academic Publishers, Boston, pp 387–408
Celik T, Iyisoy A, Kardesogla E (2007) The clinical significance of microvascular impairment in patients with pure uncomplicated Diabetes mellitus. Int J Cardiol 33(4):1–2
Natali A, Vichi S, Landi P et al (2000) Coronary atherosclerosis in type II diabetes: angiographic findings and clinical outcome. Diabetologia 43(5):632–641. doi:10.1007/s001250051352
Vinik A, Flemmer M (2002) Diabetes and macrovascular disease. J Diabetes Complicat 16:235–245. doi:10.1016/S1056-8727(01)00212-4
Fowler MJ (2008) Microvascular and macrovascular complications of diabetes. Clin Diabetes 26:77–82. doi:10.2337/diaclin.26.2.77
Goraya TY, Liebson CL, Palumbo PJ (2002) Coronary atherosclerosis in DM: a population based study. J Am Coll Cardiol 40:946–953. doi:10.1016/S0735-1097(02)02065-X
Dortimer A, Shenoy P, Shiroff R (1978) Diffuse coronary disease in diabetics: fact or fiction? Circulation 57:133–136
Butler R (1998) The clinical implications of diabetic heart disease. Eur Heart J 19:1617–1627. doi:10.1053/euhj.1998.1284
Berry C, Tardif JC, Bourassa MG (2007) Coronary heart disease in patients with diabetes—Part I: recent advances in prevention and noninvasive management. Am Coll Cardiol 49(6):631–642. doi:10.1016/j.jacc.2006.09.046
World Heart Federation Fact Sheet (2002) Available via http://www.world-heart-federation.org/cardiovascular-health/cardiovascular-disease-risk-factors/diabetes/. Accessed 3 May 2008
Grundy SM, Balady GJ, Criqui MH (1998) Primary prevention of CHD: guidance from Framingham. Circulation 97:1876–1887
Lee ET, Howard BV, Wang W et al. (2007) Prediction of CAD in patients with diabetes and albuminuria. Cardiol Rev Available at http://www.cardiologyreviewonline.com/issues/2007-12.asp. Accessed 18 Feb 2008
Mowla A, Dastgheib SA, Chodedri A (2007) Chronic renal failure and diabetes mellitus: are they comparable risk factors of coronary artery disease? South Med J 100:1
Mazeika P, Prasad N, Bui S et al (2003) Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus. Am Heart J 145(6):1013–1021. doi:10.1016/S0002-8703(03)00085-1
Haffner SM, Agostino RD Jr, Saad MF et al (2000) Carotid artery atherosclerosis in type-2 diabetic and nondiabetic subjects with and without symptomatic coronary artery disease (The Insulin Resistance Atherosclerosis Study). Am J Cardiol 85(12):1395–1400. doi:10.1016/S0002-9149(00)00784-0
Sprafka JM, Burke GL, Folsom AR et al (1991) Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival: the Minnesota heart survey. Diabetes Care 14(7):537–543. doi:10.2337/diacare.14.7.537
Hong S, Kim MH, Ahn TH et al (2006) Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes. Heart 92:1119–1124. doi:10.1136/hrt.2005.075960
Rutter MK, Marshall SM, Mccomb JM (1997) Coronary artery disease and diabetes. Heart 78:527–529
Buyken AE, Von Eckardstein A, Schulte AB et al (2007) Type 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM study. Eur J Cardiovasc Prev Rehabil 14(2):230–236. doi:10.1097/HJR.0b013e3280142037
He Z, Rask-Madsen M, King GL (2003) Managing heart disease: mechanisms of cardiovascular complications in diabetes and potential new pharmacological therapies. Eur Heart J Suppl 5(B):B51–B57
Poornima IG, Parikh P, Shannon RP (2006) Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 98:596–605. doi:10.1161/01.RES.0000207406.94146.c2
Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group (1999) Effect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications. Diabetes 48(2):383–390. doi:10.2337/diabetes.48.2.383
Aronson D, Rayfield EJ (2002) How hyperglycaemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol 1:1. doi:10.1186/1475-2840-1-1
Beckman JA, Creager M, Libby P (2002) Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287:2570–2581. doi:10.1001/jama.287.19.2570
Gleissner CA, Galkina E, Nadler JL et al. (2008) Mechanisms by which diabetes increases cardiovascular risk. Drug Discov Today. Available via http://www.sciencedirect.com/science?_ob=ArticleURL. Accessed 21 March 2008
Wold LE, Ceylan-isik AF, Ren J (2005) Oxidative stress and stress signalling: menace of diabetic cardiomyopathy. Acta Pharmacol Sin 26(8):908–917. doi:10.1111/j.1745-7254.2005.00146.x
Ramasamy R, Oates P, Schaefer S (1997) Aldose reductase inhibition protects diabetic and non diabetic rat hearts from ischaemic injury. Diabetes 46:292–300. doi:10.2337/diabetes.46.2.292
Du XL, Edelstein D, Rossetti L, Fantus IG et al (2000) Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 97:12222–12226. doi:10.1073/pnas.97.22.12222
Du XL, Edelstein D, Dimmeler S et al (2001) Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Investig 108(9):1341–1348
Nesto RW (2004) Correlation between cardiovascular disease and diabetes mellitus: current concepts. Am J Med 116(5)1:11–22
Farhangkhoee H, Khan ZA, Kaur H et al (2006) Vascular endothelial dysfunction in diabetic cardiomyopathy: pathogenesis and potential treatment targets. Pharmacol Ther 111(2):384–399
Asbun J, Villareal FJ (2006) The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 47:693–700. doi:10.1016/j.jacc.2005.09.050
Brownlee M, Cerami A, Vlassara HA (1988) Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315–1321
Farmer JA (2008) Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials. Curr Diabetes Rep 8:71–77. doi:10.1007/s11892-008-0013-2
Ramasamy R, Yan SF, Schmidt AM (2007) The RAGE connection to diabetes and atherosclerosis: an intertwined web of advanced glycation and inflammation. Future Lipidol 2(2):239–250. doi:10.2217/17460875.2.2.239
Park L, Raman KG, Lee KJ et al (1998) Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end products. Nat Med 4:1025–1031. doi:10.1038/2012
Figarolla JL (2007) Anti-inflammatory effects of AGE inhibitor LR-90 in human monocytes. Diabetes 56:647–655. doi:10.2337/db06-0936
Malhotra A, Singh Kang BP, Opawumi D et al (2001) Molecular biology of protein kinase C signalling in cardiac myocytes. Mol Cell Biochem 225(1–2):97–107. doi:10.1023/A:1012261903611
Guo M, Wu MH, Korompai F et al (2003) Upregulation of PKC genes and isozymes in cardiovascular tissues during early stages of experimental diabetes. Physiol Genomics 12:139–146
Rask-Madsen C, King GL (2005) Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc Biol 25:487. doi:10.1161/01.ATV.0000155325.41507.e0
Koya D, King GL (1998) Protein kinase C activation and the development of diabetic complications. Diabetes 47:859–866. doi:10.2337/diabetes.47.6.859
Evcimen ND, King GL (2007) The role of protein kinase C activation and the vascular complications of diabetes. Pharm Res 55(6):498–510. doi:10.1016/j.phrs.2007.04.016
Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615–1625 Available via http://www.medscape.com/viewarticle/505648 [Accessed 28 Febraury 2008]
Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820. doi:10.1038/414813a
Baynes JW, Thorpe SR (1999) Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48:1–9. doi:10.2337/diabetes.48.1.1
Farahmand F, Lou H, Singal PK (2003) Oxidative stress in cardiovascular complications of diabetes. In: Pierce GN, Nagano M, Zahradka P, Dhalla NS (eds) Atherosclerosis, hypertension and diabetes. Kluwer Academic Publishers, Boston, pp 387–408
Johansen JS, Harris AK, Rychly DJ, Ergul A (2005) Oxidative stress and use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol 4:5. doi:10.1186/1475-2840-4-5
Griendling KK, Fitzgerald GA (2003) Oxidative stress and cardiovascular injury: Part I: Basic mechanisms and in vivo monitoring of ROS. Circulation 108(16):1912–1916. doi:10.1161/01.CIR.0000093660.86242.BB
Kojda G, Harrison D (1999) Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 43(3):652–671. doi:10.1016/S0008-6363(99)00169-8
Vega-Lopez S, Devaraj S, Jialal I (2004) Oxidative stress and antioxidant supplementation in the management of diabetic cardiovascular disease. J Investig Med 52(1):24–32. doi:10.2310/6650.2004.11932
Nourouz-Zadeh J, Tajaddini-Sarmadi J (1995) Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes 44:1054–1058. doi:10.2337/diabetes.44.9.1054
Kaul N, Siveski-Iliskovic N, Hill M et al (1996) Probucol treatment reverses antioxidant and functional deficit in diabetic cardiomyopathy. Mol Cell Biochem 160:283–288. doi:10.1007/BF00240060
Yu DK, McLennan S, Fisher E et al (1989) Ascorbic acid metabolism and polyol pathway in diabetes. Diabetes 38:257–261. doi:10.2337/diabetes.38.2.257
Arai K, Magichi S, Fuji S et al (1987) Glycation and inactivation of human Cu–Zn-superoxide dismutase. J Biol Chem 262:16969–16972
Moreno PR, Fuster V (2004) New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 44(12):2293–2300. doi:10.1016/j.jacc.2004.07.060
Goldfine AB, Beckman JA (2008) Life and death in Denmark: lessons about diabetes and coronary heart disease. Circulation 117:1914–1917. doi:10.1161/CIRCULATIONAHA.108.767681
Schalkwijk CG, Stehouwer DA (2005) Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci 109:143–159. doi:10.1042/CS20050025
Cefalu WT (2001) Insulin resistance: cellular and clinical concepts. Exp Biol Med 226:13–26
Bajaj M, DeFronzo RA (2003) Metabolic and molecular basis of insulin resistance. J Nucl Cardiol 10:311–323. doi:10.1016/S1071-3581(03)00520-8
Hsueh W, Law RE (1999) Insulin signaling in the arterial wall. Am J Cardiol 84:21J–24J. doi:10.1016/S0002-9149(99)00353-7
Pyörälä M, Miettinen H, Laakso M et al (1998) Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen study. Circulation 98:398–404
Baron AD (1994) Hemodynamic actions of insulin. Am J Physiol 367:E187–E202
Stout RW (1971) The effect of insulin on the incorporation of (1-C) sodium acetate into the lipids of the rat aorta. Diabetologia 7:367–372. doi:10.1007/BF01219472
Defronzo R (2006) Is insulin resistance atherogenic? Atherosclerosis supp 11(4):11–15
Haffner SM, Miettinen H (1997) Insulin resistance implications for T2DM and CHD. Am J Med 103(2):152–162. doi:10.1016/S0002-9343(97)00027-2
Haffner SM (1993) Editorial: insulin and blood pressure: fact or fantasy? J Clin Endocrinol Metab 76:541–543. doi:10.1210/jc.76.3.541
Semenkovich C (2006) Insulin resistance and atherosclerosis. J Clin Investig 116(7):1813–1822. doi:10.1172/JCI29024
Hofmann S, Brownlee M (2004) Biochemistry and molecular cell biology of diabetic complications: a unifying mechanism. In: LeRoith D, Taylor SI, Olefsky JM (eds) Diabetes mellitus: a fundamental and clinical text, 3rd edn. Williams & Wilkins, Philadelphia, Lippincott, pp 1441–1457
Hurst RT, Lee RW (2003) Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management. Ann Intern Med 139:824–834
Reusch J, Draznin BB (2006) Atherosclerosis in diabetes and insulin resistance. Diabetes Obes Metab 9:455–463. doi:10.1111/j.1463-1326.2006.00620.x
Austin MA, Breslow JL, Hennekens CH et al (1988) Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260:1917–1921. doi:10.1001/jama.260.13.1917
Superko HR (2000) Small, dense, low-density lipoprotein and atherosclerosis. Curr Atheroscler Rep 2:226–231. doi:10.1007/s11883-000-0024-1
Plutzky J, Viberti G, Haffner S (2002) Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. J Diabetes Complicat 16(6):401–415. doi:10.1016/S1056-8727(02)00202-7
Lambarzi N, Renard CB, Kramer F et al (2004) Hyperlipidemia in concert with hyperglycemia stimulates the proliferation of macrophages n atherosclerotic lesions: potential role of glucose-oxidised LDL. Diabetes 53:3217–3225. doi:10.2337/diabetes.53.12.3217
Renard CB, Kramer F, Johanson F et al (2004) Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of advanced lesions. J Clin Investig 114:659–668
Tousoulis D, Charakida M, Stefanadis C (2006) Endothelial function and inflammation in CAD. Heart 92:441–444
Hayden MR, Tyagi SC (2004) Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: a malignant transformation. Cardiovasc Diabetol 3:1. doi:10.1186/1475-2840-3-1
Willerson JT, Majesly M (2001) Russell Ross, Ph.D: visionary basic scientist in cardiovascular medicine. In memoriam. Circulation 103(4):478–479
Witztum JL (1994) The oxidation hypothesis of atherosclerosis. Lancet 344(8925):793–795. doi:10.1016/S0140-6736(94)92346-9
Muir R (1992) Cardiovascular system. In: MacSween RNM, Whaley K (eds) Muir’s textbook of pathology, Chap. 12, 13th edn. Hodder and Stoughton Ltd, London
Maton A, Hopkins J, McLaughlin CW et al (1993) Human biology and health. Prentice Hall, Englewood Cliffs, NJ, USA, pp 134–173
Glagov S, Weisenberg E, Zarins CK et al (1987) Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 316:1371–1375
Tedgui A, Mallat Z (2006) Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86:515–581. doi:10.1152/physrev.00024.2005
Zaman AG, Helft G, Worthley SG et al (2000) The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 149:251–266. doi:10.1016/S0021-9150(99)00479-7
Moreno PR, Murcia AM, Palacios I et al (2000) Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 102:2180–2184
Biondi-Zoccai GL, Abbate A (2002) Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 41:1071–1077. doi:10.1016/S0735-1097(03)00088-3
McGill HC Jr, McMahan CA, Malcom GT, Oalmann MC, Strong JP (1995) Relation of glycohemoglobin and adiposity to atherosclerosis in youth: pathological determinants of atherosclerosis in youth (PDAY) research group. Arterioscler Thromb Vasc Biol 15:431–440
Dabelea D, Kinney G, Snell-Bergeon JK et al (2003) Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The coronary artery calcification in type 1 diabetes (CACTI) study. Diabetes 52:833–839. doi:10.2337/diabetes.52.11.2833
Orchard TJ, Costacon T, Kretowski A et al (2006) Type 1 diabetes and coronary artery disease. Diabetes Care 29:2528–2538. doi:10.2337/dc06-1161
Gerrity RG, Natarajan R, Nadler JL et al (2001) Diabetes-induced accelerated atherosclerosis in swine. Diabetes 50:1654–1665. doi:10.2337/diabetes.50.7.1654
Calles-Escandon J, Cipolla M (2001) Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 22(1):36–52. doi:10.1210/er.22.1.36
Esper RJ, Nordaby RA, Vilarino JO et al (2006) Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol 5:4. doi:10.1186/1475-2840-5-4
Loscalzo J, Welch G (1995) Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 38:87–104. doi:10.1016/S0033-0620(05)80001-5
Feldman CL, Stone PH (2000) Intravascular hemodynamic factors responsible for progression of coronary atherosclerosis and development of vulnerable plaque. Curr Opin Cardiol 15:430–440. doi:10.1097/00001573-200011000-00010
Stehouwer CD, Lambert J, Donker AJM (1997) Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 34(1):55–68. doi:10.1016/S0008-6363(96)00272-6
Förstermann U, Closs EI, Pollock JS et al (1994) Nitric oxide synthase isozymes: characterization, purification, molecular cloning, and functions. Hypertension 23:1121–1131
Förstermann U, Münzel T (2006) Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113:1708–1714. doi:10.1161/CIRCULATIONAHA.105.602532
Rahman S, Rahman T, Ismail A et al (2007) Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diabetes Obes Metab 9(6):767–780. doi:10.1111/j.1463-1326.2006.00655.x
Nitenberg A, Valensi P, Sachs R et al (1993) Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes 42(7):66–72. doi:10.2337/diabetes.42.7.1017
Mehta JL, Rasouli N, Sinha AK (2006) Oxidative stress in diabetes: A mechanistic overview of its effects on atherogenesis and myocardial dysfunction. Int J Biochem 38(5–6):794–803. doi:10.1016/j.biocel.2005.12.008
Shinozaki K, Kashiwagi A, Nishio K et al (1999) Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O2- imbalance in insulin-resistant rat aorta. Diabetes 48:2437–2445. doi:10.2337/diabetes.48.12.2437
Creager MA, Luscher TF (2003) Diabetes and vascular disease: pathophysiology, clinical consequences and medical therapy-part 1. Circulation 108:1527–1532. doi:10.1161/01.CIR.0000091257.27563.32
Kinlay S, Behrendt D, Wainstein M et al (2001) The role of endothelin-1 in the constriction of human atherosclerotic coronary arteries. Circulation 104:1114–1118. doi:10.1161/hc3501.095707
Chakravarthy RG, Hayes AW, Stitt E et al (1998) Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes 47(6):945–952. doi:10.2337/diabetes.47.6.945
Tesfamariam B, Brown ML, Deykin D et al (1990) Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J Clin Investig 85:929–932. doi:10.1172/JCI114521
Cai H, Harrison DG (2000) Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87:840–844
Savoia C, Schiffrin EL (2007) Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci 112:375–384. doi:10.1042/CS20060247
Fisman EZ, Motro M, Tenenbaum A (2003) The core of a novel interleukins classification: the bad, the good and the aloof. Cardiovasc Diabetol 2:11. doi:10.1186/1475-2840-2-11
Biondi-Zoccai G, Abbate A, Liuzzo G et al (2003) Atherothrombosis, inflammation and diabetes. J Am Coll Cardiol 41:1071–1077. doi:10.1016/S0735-1097(03)00088-3
Alexandraki K, Piperi C, Kalofoutis C et al (2006) Inflammatory process in type 2 diabetes: the role of cytokines. Ann NY Acad Sci 1084:89–117. doi:10.1196/annals.1372.039
Sánchez PL, Moriñigo JL, Pabón P et al (2004) Prognostic relations between inflammatory markers and mortality in diabetic patients with non-ST elevation acute coronary syndrome. Heart 90:264–269. doi:10.1136/hrt.2002.007443
Hamuro M, Polan J, Natarajan M et al (2002) High glucose induced nuclear factor kappa B mediated inhibition of endothelial cell migration. Atherosclerosis 2:277–287. doi:10.1016/S0021-9150(01)00719-5
Collins T, Cybulsky MI (2001) NF-κB: pivotal mediator or innocent bystander in atherogenesis? J Clin Investig 107(3):255–264. doi:10.1172/JCI10373
Brand K, Page S, Rogler G et al (1996) Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Investig 97:1715–1722. doi:10.1172/JCI118598
Fischer CP, Perstrup LB, Berntsen A et al (2005) Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans. Clin Immunol 117:152–160. doi:10.1016/j.clim.2005.07.008
Sjoholm D, Nostrom T (2005) Endothelial inflammation in insulin resistance. Lancet 365(9459):610–612
Lin L, Qi Z, Li-jin P et al (2007) Elevation of tumor necrosis factor-α, interleukin-1β and interleukin-6 levels in aortic intima of Chinese Guizhou minipigs with streptozotocin-induced diabetes. Chin Med J 120(6):479–484
Hansson GK, Libby P (2006) The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6(7):508–519. doi:10.1038/nri1882
Schultz K, Rusmussen LM, Ledet T (2005) Expression levels and functional aspects of the hyaluron receptor CD44. Effects of insulin, glucose, IGF-1 or growth hormone on human arterial smooth muscle cells. Metabolism 54:287–295. doi:10.1016/j.metabol.2004.09.007
Shah PK (2000) Plaque disruption and thrombosis: potential role of inflammation and infection. Cardiol Rev 8:31–39. doi:10.1097/00045415-200008010-00007
Marfella R, Amico MD, DiFilippo C et al (2007) The possible role of the ubiquitin proteasome system in the development of atherosclerosis in diabetes. Cardiovasc Diabetol 6:35. doi:10.1186/1475-2840-6-35
Weyrich AS (2004) Platelets: signaling cells inside the immune continuum. Trends Immunol 25:489–495. doi:10.1016/j.it.2004.07.003
Winocour DW, Perry RL, Kinlough-Rathbone F (1992) Hypersensitivity to ADP of platelets from diabetic rats associated with enhanced fibrinogen binding. Eur J Clin Investig 22(1):19–23. doi:10.1111/j.1365-2362.1992.tb01930.x
Li Y, Woo V, Bose R (2001) Platelet hyperactivity and abnormal Ca2+ homeostasis in diabetes mellitus. Am J Physiol Heart Circ Physiol 280:H1480–H1489
Vinik AL, Erbas T, Sun Park T (2001) Platelet dysfunction in type 2 diabetes. Diabetes Care 24:1476–1485. doi:10.2337/diacare.24.8.1476
Carr ME (2001) Diabetes mellitus: a hypercoagulable state. J Diabetes Complic 15:44–45. doi:10.1016/S1056-8727(00)00132-X
Morale M, De Negri F, Carmassi F (1997) Fibrin(ogen) and DM: don’t forget fibrinolysis. Diabetologia 40:735–737. doi:10.1007/s001250050742
Sambola A, Fuster V, Badimon JJ (2003) Role of coronary risk factors in blood thrombogenicity and acute coronary syndromes. Circulation 107:973–977. doi:10.1161/01.CIR.0000050621.67499.7D
Felmeden DC, Blann AD, Lip GY (2003) Angiogenesis: basic pathophysiology and implications for heart disease. Eur Heart J 24(7):586–603. doi:10.1016/S0195-668X(02)00635-8
Fam NP, Verma S, Kutryk M (2003) Clinician guide to angiogenesis. Circulation 108:2613. doi:10.1161/01.CIR.0000102939.04279.75
Simons M (2005) Angiogenesis, arteriogenesis, and diabetes. J Am Coll Cardiol 46:835–837. doi:10.1016/j.jacc.2005.06.008
Purushothaman KR, Fuster V, O’Connor W et al (2003) Neovascularization, inflammation and intra-plaque hemorrhage are increased in advanced human atherosclerosis from patients with diabetes mellitus. Circulation 108:459–469
Fadini GP, Agostini C, Avogaro A (2005) Endothelial progenitor cells and vascular biology in DM: current knowledge and future perspectives. Curr Diabetes Rep 1:41–58. doi:10.2174/1573399052952640
Sasso FC, Torella D, Carbonara O (2005) Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. J Am Coll Cardiol 46:827–834. doi:10.1016/j.jacc.2005.06.007
Aronson D, Rayfield EJ, Chesebro JH (1997) Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med 126:296–306
Abaci A, Oguzhan A, Kahraman S et al (1999) Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 99:2239–2242
Waltenberger J (2001) Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc Res 49:554–560. doi:10.1016/S0008-6363(00)00228-5
Waltenberger J, Lange J, Kranz A (2000) Vascular endothelial growth factor-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus. A potential predictor for the individual capacity to develop collaterals. Circulation 102:185–190
Arras M, Ito WD, Scholz D et al (1998) Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Investig 101:40–50. doi:10.1172/JCI119877
Schaper W, Ito WD (1996) Molecular mechanisms of coronary collateral vessel growth. Circ Res 79:911–919
Feener EP, King GL (1997) Vascular dysfunction in diabetes mellitus. Lancet 350:9–13. doi:10.1016/S0140-6736(97)90022-2
Aiello LP, Wong JS (2000) Role of VEGF in diabetic vascular complications. Kidney Int Suppl 77:S113–S119. doi:10.1046/j.1523-1755.2000.07718.x
Hristov M, Erl W, Weber PC (2003) Endothelial progenitor cells: isolation and characterisation. Trends Cardiovasc Med 13(5):201–206. doi:10.1016/S1050-1738(03)00077-X
L’Abbate A (2005) Large and micro coronary vascular involvement in diabetes. Pharmacol Rep 57:3–9
Nesto RW, Zarich S (1998) Acute myocardial infarction in diabetes mellitus: lessons learned from ACE inhibition. Circulation 97:12–15
Fang YH, Johannes BP, Marwick TH (2004) Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 25(4):543–567. doi:10.1210/er.2003-0012
Harrower AD, Small DR, Railton R (1986) Variability of left ventricular function at diagnosis and after treatment in insulin-dependent diabetes. Diabetes Res 3:149–152
Krentz AJ, Clough G, Byrne CD (2007) Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications. Diabetes Obes Metab 9(6):781–791. doi:10.1111/j.1463-1326.2007.00670.x
Avogaro A, Fadini G, De Kreutzenberg SV et al (2007) Coronary heart disease in diabetes. Int Congr Ser 1303:70–73. doi:10.1016/j.ics.2007.04.006
Scognamiglio R, Negut C, De Kreutzenberg SV et al (2005) Postprandial myocardial perfusion in healthy subjects and type 2 diabetic patients. Circulation 112(2):179–184. doi:10.1161/CIRCULATIONAHA.104.495127
Camici PG, Crea F (2007) Coronary microvascular dysfunction. N Engl J Med 356:830–840. doi:10.1056/NEJMra061889
Barrett-Connor E (2004) Cardiovascular risk stratification and cardiovascular risk factors associated with erectile dysfunction: assessing cardiovascular risk in men with erectile dysfunction. Clin Cardiol 27(1):I8–I13
Molitch ME, DeFronzo RA, Franz MJ et al (2004) Nephropathy in diabetes. Diabetes Care 27(1):S79–S83. doi:10.2337/diacare.27.2007.S79
Wong TY, Klien R, Couper DJ et al (2001) Retinal microvascular abnormalities and incident stroke: the atherosclerosis risk in communities study. Lancet 358:1134–1140. doi:10.1016/S0140-6736(01)06253-5
Lockhart CJ, Hamilton PK, McVeigh K et al (2008) A cardiologist view of vascular disease in diabetes. Diabetes Obes Metab 10(4):279–292. doi:10.1111/j.1463-1326.2007.00727.x
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
D’Souza, A., Hussain, M., Howarth, F.C. et al. Pathogenesis and pathophysiology of accelerated atherosclerosis in the diabetic heart. Mol Cell Biochem 331, 89–116 (2009). https://doi.org/10.1007/s11010-009-0148-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-009-0148-8